Second-line chemotherapy efficacy is not affected by prior exposure to immunotherapy in extensive-disease small-cell lung cancer: results from the ESME French national real-world cohort
Aug 2026· ESMO Open· Vol 11, pp. 108324· 0 citations· 26 references
Medicine
TL;DR
This study showed no OS gain in second-line treatment among patients pretreated with immunotherapy compared with those who received chemotherapy alone as first-line treatment.
Abstract
Background Extensive-disease small-cell lung cancer (ED-SCLC) is an aggressive disease with limited effective therapeutic options. Clinical trials suggest an additive effect of chemotherapy and immunotherapy in SCLC, although the magnitude of benefit seems to be limited. Considering the prolonged peripheral persistence of anti-PD-(L)1 blockade, we wanted to investigate the impact of prior immunotherapy exposure on the efficacy of second-line chemotherapy. Patients and methods Using the Epidemio-Strategy and Medical Economics lung cancer national real-world database, we selected ED-SCLC patients diagnosed between 17 February 2010 and 4 December 2023 who had received at least two lines of treatment for a metastatic disease with platinum-based regimens in the first-line setting. Second-line real-world progression-free survival (rw-PFS) and overall survival (OS) were analyzed according to first-line immunotherapy exposure using a multivariable Cox proportional hazards model and a propensity score-weighted sensitivity analysis. Results The study included 2051 patients with ED-SCLC: 638 (30%) in the immunotherapy-pretreated group and 1413 (70%) who received only first-line chemotherapy. Multivariable analysis showed no significant difference in second-line median rw-PFS between immunotherapy-pretreated patients [2.9 months, 95% confidence interval (CI) 2.7-3.3] and chemotherapy-only pretreated patients (2.5 months, 95% CI 2.4-2.7) (hazard ratio 0.94, 95% CI 0.85-1.04, P = 0.21). Similar results were observed in the propensity score adjusted Cox regression sensitivity analysis. A longer median OS from the start of second-line treatment was observed in immunotherapy-pretreated patients (6.6 months, 95% CI 6.1-7.1 compared with 5.7 months, 95% CI 5.4-6.1, P = 0.03) although, this result has not been confirmed in a more contemporary cohort. Conclusion This study showed no OS gain in second-line treatment among patients pretreated with immunotherapy compared with those who received chemotherapy alone as first-line treatment.
This real-world analysis shows poor outcomes in patients with progressing ES-SCLC, reflected by both short median PFS and duration of second-line treatment, along with high rates of treatment discontinuation due to progression, highlighting the urgent need for more effective and tolerable treatment options.
Daniel Moser, A. Lang-Stöberl, H. Fabikan et al.· Lung Cancer· 0 citations
Background Extensive-stage small cell lung cancer (ES-SCLC) is highly aggressive with dismal prognosis, and platinum monochemotherapy offers modest long-term survival. Multiple first-line regimens integrating immunotherapy, anti-angiogenic agents and chemotherapy have been approved, yet direct head-to-head comparisons...
Hong-Jing Yu, Jun-Chen Liu, Dong-Sheng Zhang et al.· Frontiers in Pharmacology· 0 citations
For patients with a CFI exceeding 90 days, platinum rechallenge represents a rational second-line treatment strategy and remains relevant despite the introduction of first-line chemoimmunotherapy, as a substantial proportion of patients still relapse within 180 days.
A. Eijkelboom, B. Peters, D. Dumoulin et al.· Lung Cancer· 0 citations
The type of immune checkpoint inhibitor used in combination with chemotherapy did not significantly influence treatment outcomes, however, the presence of liver metastases emerged as a major adverse prognostic factor associated with shorter OS and PFS in patients with ES-SCLC treated with chemoimmunotherapy.
A. Łomża-Łaba, M. Knetki-Wróblewska, Michał Gil et al.· Oncology Research· 0 citations
Real-world evidence is provided supporting the use of ICI-based therapy in SCLC, particularly in advanced-stage disease, but should be interpreted cautiously given the retrospective design and subgroup sample sizes.
Peng-Hu Gao, Hong-Bing Zhang, Ming-Hui Liu et al.· Frontiers in Oncology· 0 citations
Immune checkpoint inhibitors alone or in combination with platinum-based doublet chemotherapy is the standard first-line treatment for patients with metastatic non-small cell lung cancer (mNSCLC) without driver mutations. It should be recognized, however, that treating patients who are not eligible for platinum-based c...
A. Kornietskaya, S. Evdokimova, N. S. Prizova et al.· Meditsinskiy sovet = Medical...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.